Apogee Therapeutics chairman Mark McKenna (L), and CEO Michael Henderson
August 21, 2023 07:30 AM EDT
People

Af­ter Prometheus sale, Mark McKen­na heads to an­oth­er au­toim­mune biotech as chair of Apogee

Kyle LaHucik

Senior Reporter

Af­ter Mark McKen­na sold a biotech for $10.8 bil­lion, the ex­ec­u­tive re­cruiters like­ly came knock­ing, try­ing to poach the CEO who took an im­munol­o­gy and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times